Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 1/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 19/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zinviroxime SCHEMBL149064 | 1.00 | PI4KB (1.00) | PI4KBMAPK14CYP3A4 | |
| Enviroxime SCHEMBL3585 | 1.00 | PI4KB (1.00) | PI4KBMAPK14CYP3A4 | |
| Viroxime SCHEMBL29365398 | 1.00 | PI4KB (1.00) | PI4KBMAPK14CYP3A4 | |
| Enviroxime SCHEMBL6475190 | 0.86 | PI4KB (0.74) | PI4KBMAPK14CYP3A4 | |
| SCHEMBL10906292 | 0.85 | PI4KB (0.74) | PI4KBMAPK14CYP3A4 | |
| SCHEMBL4837467 | 0.85 | PI4KB (0.74) | PI4KBMAPK14CYP3A4 | |
| SCHEMBL11073939 | 0.84 | PI4KB (0.72) | PI4KBMAPK14CYP3A4 | |
| SCHEMBL11149101 | 0.83 | PI4KB (0.71) | PI4KBMAPK14CYP3A4 | |
| Enviradene SCHEMBL10429409 | 0.83 | PI4KB (0.71) | PI4KBMAPK14CYP3A4 | |
| Enviradene SCHEMBL29367493 | 0.83 | PI4KB (0.71) | PI4KBMAPK14CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1957 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114432303-A | Application of panobinostat in preparation of medicine for preventing and treating coronavirus | 中国科学院深圳先进技术研究院 | 2022-05-06 | — | — | CN | claimed |
| CN-114432287-A | Application of ITF2357 in preparation of medicine for preventing and treating coronavirus | 中国科学院深圳先进技术研究院 | 2022-05-06 | — | — | CN | claimed |
| CN-114432305-A | Application of CAY10603 in preparing medicine for preventing and treating coronavirus | 中国科学院深圳先进技术研究院 | 2022-05-06 | — | — | CN | claimed |
| WO-2022088047-A1 | APPLICATION OF ITF2357 IN PREPARATION OF DRUG FOR PREVENTING AND TREATING CORONAVIRUSES | 中国科学院深圳先进技术研究院 | 2022-05-05 | — | — | WO | claimed |
| WO-2022088038-A1 | APPLICATION OF CAY10603 IN PREPARATION OF DRUGS FOR PREVENTING AND TREATING CORONAVIRUS-RELATED DISEASES | 中国科学院深圳先进技术研究院 | 2022-05-05 | — | — | WO | claimed |
| WO-2022088037-A1 | APPLICATION OF SIRTINOL IN PREPARATION OF DRUG FOR PREVENTING AND TREATING CORONAVIRUS | 中国科学院深圳先进技术研究院 | 2022-05-05 | — | — | WO | claimed |
| WO-2022088025-A1 | APPLICATION OF PANOBINOSTAT IN PREPARING DRUG FOR PREVENTION AND TREATMENT OF CORONAVIRUS | 中国科学院深圳先进技术研究院 | 2022-05-05 | — | — | WO | claimed |
| WO-2021253338-A1 | USE OF ROMIDEPSIN IN PREVENTING AND TREATING CORONAVIRUS-RELATED DISEASES | 中国科学院深圳先进技术研究院 | 2021-12-23 | — | — | WO | claimed |
| CN-113813366-A | Application of romidepsin in preparation of medicine for preventing and treating novel anti-new-crown-pneumonia coronavirus | 中国科学院深圳先进技术研究院 | 2021-12-21 | — | — | CN | claimed |
| US-20210299143-A1 | USE OF ANTAGONISTS TO THE NUCLEAR STEROID RECEPTOR TO INHIBIT CORONAVIRUSES | Spectral Analytics, Inc. (US) | 2021-09-30 | — | — | US | claimed |
| US-4956351-A | INCLUSION COMPLEXESOFVIRICIDES; RHINITIS; SUSTAINED RELEASE; NONIRRITATING TO MUCOUS MEMBRANE | JANSSEN PHARMACEUTICA N.V. FRAME-543 (BE) | 1990-09-11 | — | — | US | claimed |
| WO-1990006775-A1 | A NOVEL NONPHOSPHOLIPID LIPOSOME COMPOSITION FOR SUSTAINED RELEASE OF DRUGS | LIPOSOME TECHNOLOGY, INC. (US) | 1990-06-28 | — | — | WO | claimed |
| EP-0207116-A1 | IMPROVEMENTS RELATING TO THE TREATMENT CONTROL AND PREVENTION OF RHINOVIRUS INFECTIONS | TYRRELL, David Arthur John (GB) | 1987-01-07 | — | — | EP | claimed |
| WO-1986003412-A1 | IMPROVEMENTS RELATING TO THE TREATMENT CONTROL AND PREVENTION OF RHINOVIRUS INFECTIONS | TYRRELL DAVID ARTHUR JOHN | 1986-06-19 | — | — | WO | claimed |
| EP-0047122-A2 | Intranasal formulation | ELI LILLY AND COMPANY (US) | 1982-03-10 | — | — | EP | claimed |
| US-4309258-A | Conversion of benzimidazole isomers | ELI LILLY AND COMPANY (US) | 1982-01-05 | — | — | US | claimed |
| US-4289782-A | PARTICULARLY FOR INHIBITING GROWTH OF RHINOVIRUSES | ELI LILLY AND COMPANY (US) | 1981-09-15 | — | — | US | claimed |
| EP-0015339-A1 | Separation of syn and anti 1-alkylsulfonyl-2-amino-5(6)hydroximinomethylbenzimidazole derivatives | ELI LILLY AND COMPANY (US) | 1980-09-17 | — | — | EP | claimed |
| US-4191832-A | Separation of syn and anti oximes of 1-sulfonyl-2-aminobenzimidazoles | ELI LILLY AND COMPANY (US) | 1980-03-04 | — | — | US | claimed |
| US-4118742-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1978-10-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299143-A1 | USE OF ANTAGONISTS TO THE NUCLEAR STEROID RECEPTOR TO INHIBIT CORONAVIRUSES | NCOA1, NCOA2, NCOA3 | PI4KB 3767/4885MAPK14 2822/4885CYP3A4 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.